ライフサイエンスコーパス: headache

1 dominant clinical finding is an orthostatic headache.

2 levels were associated with risk of migraine headache.

3 rse events (AEs) were insomnia, fatigue, and headache.

4 X participants were dry mouth, insomnia, and headache.

5 es turned out to be strongly associated with headache.

6 predisposition to develop different forms of headache.

7 AH in a premenopausal woman presenting with headache.

8 ommon adverse events overall were anemia and headache.

9 nderness and (2) patients with no history of headache.

10 se events were nasopharyngitis, fatigue, and headache.

11 1 month of worsening confusion, fatigue, and headache.

12 action of fremanezumab in the prevention of headache.

13 events were fatigue, insomnia, asthenia, and headache.

14 erse events being fatigue, constipation, and headache.

15 urs avoid light because it intensifies their headache.

16 e most common drug-related adverse event was headache.

17 acks of angioedema, injection-site pain, and headache.

18 e injection-site pain, fatigue, myalgia, and headache.

19 by fever, polyarthralgia, myalgia, rash, and headache.

20 e who received placebo reported dizziness or headache.

21 ystem function rather than simply a vascular headache.

22 ause of diplopia and progressively worsening headaches.

23 associated with significantly higher odds of headaches.

24 .5%]) and odds (1.52 [95% CI, 1.45-1.59]) of headaches.

25 cts and in 20 control patients with migraine headaches.

26 are extracranial pathophysiologies in these headaches.

27 seizures and 17/84 (20%) reported recurrent headaches.

28 s (14 patients [13%]), influenza (13 [12%]), headache (11 [10%]), and upper respiratory tract infecti

29 se events were asthenia (16 [39%] patients), headache (11 [27%] patients), and fatigue (four [10%] pa

30 ain and/or dyspnea (14%), and 49 of 433 with headache (11%) returned for the same indication.

31 fection (15 [5%] vs 15 [5%] vs 11 [4%]), and headache (12 [4%] vs 17 [6%] vs 11 [4%]).

32 common adverse events with eltrombopag were headache (13 [30%] patients receiving eltrombopag vs nin

33 st common adverse events were fatigue (25%), headache (13%), upper respiratory tract infection (8%),

34 -week group; 20 [33%] in the 16-week group), headache (14 [23%] in the 12-week group; 14 [23%] in the

35 The most common adverse event was headache (14 [29%] of 49 treatment-experienced patients

36 rse events were nausea (39 [7%] vs 18 [7%]), headache (16 [3%] vs 12 [5%]), and dizziness (12 [2%] vs

37 gue (48%), insomnia (19%), nausea (18%), and headache (16%).

38 and eight [16%] patients, respectively), and headache (17 [15%] patients in each group).

39 ite reactions (7% vs 40%, respectively), and headache (17% vs 20%).

40 mmon adverse events in the active group were headache (17%), fatigue (16%), and nausea (9%).

41 , nausea (31/242 [13%] vs 34/242 [14%]), and headache (17/242 [7%] vs 12/242 [5%]).

42 2 patients), nasopharyngitis (18 [15%]), and headache (18 [15%]) in the tight control group, and wors

43 Headache (1832 [25.4%]), fatigue (1361 [18.9%]), and mus

44 up); and nervous system disorders, including headache (19 [4%] vs 11 [3%] patients) and dizziness (ni

45 ain and/or dyspnea (19%), and 81 of 426 with headache (19%).

46 lation would have emerged even if only 1% of headache (2% of migraine) instances were caused by geoma

47 events were nausea (31.0%), chills (23.8%), headache (21.4%), and infusion-related reaction (21.4%);

48 events were fatigue (29%), nausea (23%), and headache (22%) in all patients and anemia (31%) in the p

49 se events were fatigue (in 38% of patients), headache (23%), and anemia (21%).

50 eported adverse events were nausea (27%) and headache (23%).

51 in and/or dyspnea (42%), and 103 of 433 with headache (24%).

52 The most common adverse events were headache (25%), fatigue (21%), and diarrhea (11%).

53 ents were fatigue (30%), diarrhea (28%), and headache (25%).

54 reactogenic events were fatigue (29 [43%]), headache (26 [39%]), and malaise (15 [22%]).

55 The most common adverse events were headache (26% of patients), fatigue (21%), and nausea (1

56 29 [39%]), diarrhoea (34 [42%] vs 20 [27%]), headache (27 [33%] vs seven [9%]), peripheral neuropathy

57 e most commonly reported adverse events were headache (27% of patients), diarrhea (14%), and fatigue

58 sh, arthralgias, conjunctival injection, and headache; 27% had fever (short-term and low-grade).

59 patients), musculoskeletal pain (303 [38%]), headache (278 [35%]), depression (124 [17%] of 713 respo

60 49 [20%] of 247 in the atazanavir group) and headache (28 [11%] vs 32 [13%]).

61 is (65.9%), cranial nerve palsy (43.4%), and headache (28.3%).

62 yrexia (58%), febrile neutropenia (40%), and headache (31%).

63 ity, and the most common adverse events were headache (35 [21%] of 166) and fatigue (28 [17%] of 166)

64 st common adverse events were fatigue (51%), headache (36%), and nausea (23%).

65 se events in patients without cirrhosis were headache (41 [41%]) and fatigue (35 [35%]).

66 , nasopharyngitis (56 [10%] vs 16 [5%]), and headache (42 [7%] vs 22 [8%]).

67 erse events were fatigue (51 patients, 23%), headache (44, 20%), nausea (32, 15%), and diarrhoea (21,

68 turbances (75.3%), erythema migrans (59.7%), headache (46.8%), fatigue (44.2%), malaise (39%), parest

69 events were primarily grade 1 or 2 and were headache (47 [38%]), diarrhoea (38 [31%]), fatigue (34 [

70 al neurologic dysfunction (7.1%), and severe headaches (5.3%).

71 Overall, the most common adverse events were headache (55 [23%] of 240), fatigue (47 [20%] of 240), a

72 quent were anorexia (79.2%), nausea (75.5%), headache (60.4%), amnesia (58.5%), and >5% weight loss (

73 ects associated with tasimelteon in SET were headache (7 [17%] of 42 patients given tasimelteon vs 3

74 , fatigue (88.3%), loss of appetite (87.0%), headache (77.9%), joint pain (73.7%), vomiting (71.2%),

75 The main clinical features were headache, a cerebellar syndrome, memory impairment, and

76 ola virus disease (EVD) symptoms (eg, fever, headache, abdominal pain, diarrhea, emesis, and fatigue)

77 Severe headache, altered mental status, meningeal signs, and ot

78 (3.8%) experienced the adverse event of mild headache and 3 (2.8%) discontinued scalp cooling due to

79 CT) or magnetic resonance imaging (MRI) (for headache and back pain), and referrals to other physicia

80 improving neurologic diagnosis, particularly headache and cerebrovascular disease.

81 migraine days per month were enrolled at 59 headache and clinical research centres in North America

82 ears with chronic migraine, enrolled from 69 headache and clinical research centres in North America

83 l presentation runs a spectrum, ranging from headache and dizziness to coma and death, with a mortali

84 History A 53-year-old man experienced headache and double vision that progressed over 1 year.

85 most common non-serious adverse events were headache and fatigue.

86 rease in the incidence of postdural-puncture headache and in the need for patients to return to hospi

87 The most common adverse events were headache and nasopharyngitis.

88 n outside facility with a chief complaint of headache and pain behind his right eye.

89 role in the initiation of the perception of headache and the development of cutaneous allodynia and

90 admission to further evaluate the patient's headache and the mass on the patient's forehead.

91 Of these serious adverse events, headache and thrombocytosis, in one (2%) of 42 patients

92 rease in the nongastrointestinal symptoms of headache and tiredness (P = .010).

93 se events were mild in severity and included headache and upper gastrointestinal events.

94 st common adverse events in both groups were headache and upper respiratory tract infection (ten [16%

95 Headache and visual disturbances including loss of visio

96 ort a patient presenting with prolonged mild headaches and acute onset of seizure like activity found

97 eomagnetic activity and the onset of primary headaches and migraines.

98 ds to human use and may explain why fatigue, headaches and nervousness have been reported as side eff

99 her 60s presented with a history of chronic headaches and progressive encephalopathy.

100 fa as part of a clinical trial, he developed headaches and right-hand weakness and was found to have

101 hildhood eczema is associated with increased headaches and whether such association is related to fat

102 gns of cerebral edema (nausea, vomiting, and headache) and intervene with IV 3% sodium chloride as th

103 esented with a three-week history of frontal headache, and 'blurriness' in the left side of her visio

104 rrent CRS symptoms, 1,765 (23%) had migraine headache, and 1,930 (25%) had higher levels of fatigue.

105 th a >/=50% reduction in cumulative hours of headache, and 56.3%, 14.5% and 7.7% of patients first re

106 lthy, and presented with syndromes of fever, headache, and altered consciousness.

107 he reported additional symptoms of weakness, headache, and arthralgia primarily involving her bilater

108 ns; 28 adverse events, most commonly nausea, headache, and arthralgia, resulted in interruption of Pr

109 are facility in southern Vietnam with fever, headache, and arthralgia.

110 The most common AEs were fatigue, headache, and diarrhea.

111 (incidence 5%) for vortioxetine were nausea, headache, and diarrhea.

112 he most frequent adverse events were nausea, headache, and fatigue (12-week arm: 15% [23/155], 14% [2

113 is associated with nasal and sinus, migraine headache, and fatigue symptoms in a general population r

114 as development and nasal and sinus, migraine headache, and fatigue symptoms in Pennsylvania.

115 with chronic rhinosinusitis (CRS), migraine headache, and fatigue symptoms.

116 /50 groups, respectively; transient myalgia, headache, and fatigue were the commonest systemic advers

117 he most common adverse events were asthenia, headache, and fatigue.

118 ole discontinued treatment owing to malaise, headache, and moderate dizziness (Common Terminology Cri

119 ted to the hospital with a persistent fever, headache, and myalgia.

120 The most common AEs were fatigue, headache, and nausea.

121 up significantly improved papilledema grade, headache, and QoL measures.

122 mnia, akathisia, worsening of schizophrenia, headache, anxiety) were reported in 123 (54%) patients t

123 Headache, anxiety, dissociation, nausea, and dizziness w

124 We included 50 patients with stroke and headache as well as 50 patients with stroke but no heada

125 halamus were selectively associated with the headache attack frequency, meaning that the varying ampl

126 nucleus and was selectively associated with headache attack frequency.

127 actory short-lasting unilateral neuralgiform headache attack patients who have failed other therapies

128 TICLE: Short-lasting unilateral neuralgiform headache attacks are primary headache disorders characte

129 actory short-lasting unilateral neuralgiform headache attacks underwent ipsilateral ventral tegmental

130 ough, musculoskeletal pain, nasopharyngitis, headache, back pain, and diarrhea.

131 Sumatriptan, a drug commonly used to treat headaches, blocked the vascular and behavioral the effec

132 silent cerebral infarcts (39% by 18 years), headache (both acute and chronic: 36% in children with s

133 mplicated in the pathophysiology of migraine headache, but its role in migraine is still equivocal.

134 heals and flares, flushing, tachycardia, and headache, but not gastrointestinal symptoms), and reduct

135 tial explanation for selectivity to migraine headache, but not other pains, and a predominantly perip

136 limited to pathological conditions, such as headaches, but little is known about the dural blood flo

137 mothers (65.0%), fever by 9 mothers (22.5%), headache by 9 mothers (22.5%), and arthralgia by 8 mothe

138 New onset of sudden or progressive headache can have various causes, including disorders of

139 including coronary artery disease, migraine headache, cervical artery dissection, fibromuscular dysp

140 Adverse events were infrequent and included headache, chest pressure, and orthostatic symptoms.

141 with nonspecific symptoms, including fever, headache, chills, myalgia, and arthralgia.

142 other adverse events were mild: short-lived headaches coincident with seasonal allergies occurred in

143 s assessed using data from the International Headache Consortium (23,285 cases, 95,425 controls) and

144 in traditional medicine for the treatment of headaches, coughs, and diarrhea.

145 ents (n=688) 49.3% had a >/=50% reduction in headache-day frequency during treatment cycle 1, with 11

146 oup had a significantly greater reduction in headache days (-3.4 vs. -2.0 days/month, p = 0.025).

147 The mean number of baseline headache days (as defined above) per month was 13.2, 12.

148 hange from baseline in the average number of headache days (defined as days in which headache pain la

149 ve reduction of 50% or more in the number of headache days in the comparison of the 28-day baseline p

150 ion of at least 50% in the average number of headache days per month was 38% in the fremanezumab-quar

151 n (+/-SE) reduction in the average number of headache days per month was 4.3+/-0.3 with fremanezumab

152 Chronic migraine was defined as 15 or more headache days per month, of which eight or more were mig

153 nts who first achieved a >/=50% reduction in headache days, moderate/severe headache days, total cumu

154 y outcomes were headache-related disability, headache days, number of trial completers, and serious a

155 days, total cumulative hours of headache on headache days, or a >/=5-point improvement in Headache I

156 differences in headache-related disability, headache days, or the percentage of patients who complet

157 reduction in headache days, moderate/severe headache days, total cumulative hours of headache on hea

158 endpoint was change relative to baseline in headache-days during weeks 9-12.

159 s change in the number of moderate or severe headache-days in weeks 9-12 relative to baseline.

160 Once the headache develops, it typically throbs, intensifies with

161 hat hypercalcaemia is comorbid with migraine headache diagnoses, and that genetically elevated serum

162 The most common adverse events were headache, diarrhea, fatigue, and nausea.

163 QoL and headache disability scores showed significant improvemen

164 sabling, recurrent, hereditary neurovascular headache disorder.

165 al neuralgiform headache attacks are primary headache disorders characterized by short-lasting attack

166 ted disorders, several movement, seizure and headache disorders have been linked to PRRT2 mutations i

167 one [7%] of 15 patients for each event), and headache, dizziness, diarrhoea, and vomiting were the mo

168 reported on a soldier with relapsing fever, headache, dizziness, lumbago, and shin pain.

169 Side effects of headaches, eyestrain, avoidance of near activities, and

170 The most common adverse events were headache, fatigue, and nausea.

171 The most common adverse events were headache, fatigue, and nausea.

172 adverse events (in >/=10% of patients) were headache, fatigue, diarrhea, and nausea.

173 The most common adverse events were headache, fatigue, diarrhea, and nausea.

174 Overall, the most common adverse events were headache, fatigue, diarrhea, and nausea; diarrhea and na

175 p and two in the placebo group, and included headache, fever, and malaise).

176 bo were nasopharyngitis (11 and five vs 12), headache (five and three vs eight), and urinary-tract in

177 kemia presented with 1 month of intermittent headaches followed by a seizure.

178 nsient nausea (four patients), and transient headache (four patients).

179 e no significant differences in reduction in headache frequency or headache-related disability in chi

180 Headache, gastrointestinal upset, sleep disturbance, and

181 Between the headache group as well as the non-headache there was no

182 ternal and environmental triggers of primary headaches have been proposed, but establishing firm evid

183 t square mean difference in the reduction of headache-hours between the placebo and 675/225 mg dose g

184 The mean change from baseline in number of headache-hours during weeks 9-12 was -59.84 h (SD 80.38)

185 on (HR, 4.9; 95% CI, 3.2 to 7.5); and severe headaches (HR, 3.2; 95% CI, 1.9 to 5.4).

186 s were reported by seven patients: dyspnoea, headache, hypertension, intervertebral disc protrusion,

187 Mass effects cause headache, hypopituitarism, and visual field defects.

188 eadache days, or a >/=5-point improvement in Headache Impact Test (HIT)-6.

189 ve performance deficits and more substantial headache impairment than control subjects.

190 potential lesional patterns associated with headache in acute ischaemic stroke.

191 ons, which are related to the development of headache in acute ischaemic stroke.

192 lus vitamin D is effective for prevention of headache in adults with episodic migraine.

193 n gene-related peptide (CGRP), which induces headache in humans.

194 ergy, eczema was found to be associated with headaches in 14 of 19 studies.

195 Eczema is associated with increased headaches in childhood, particularly in patients with se

196 Sleep disturbances have been shown to cause headaches in childhood.

197 rted having a 2-week history of intermittent headaches in December 2011, when he presented with acute

198 use of onabotulinumtoxinA for prophylaxis of headaches in patients with chronic migraine (CM) involve

199 ed with 6.8% of those in the placebo group), headache (in 25.1% and 31.9%, vs. 16.9%), muscle pain (i

200 The most common adverse events observed were headache (in 43% of the patients), diarrhea (in 39%), an

201 adverse event, the most common of which were headache (in 45 [16%] given mepolizumab vs 59 [21%] give

202 The primary outcome of postdural-puncture headache incidence and additional safety and efficacy ou

203 P = 0.03) between serum calcium and migraine headache, indicating that these traits have a genetic ba

204 Patients reported headache information daily using an electronic diary.

205 Daily headache information was captured using an electronic di

206 eported adverse events were fatigue, nausea, headache, insomnia, and rash.

207 ht is more complex than its association with headache intensification.

208 /mPFC was associated with increased migraine headache intensity at the baseline.

209 striatum were significantly associated with headache intensity improvement.

210 Headache is a common symptom in acute ischaemic stroke,

211 Headache is the most common-and often the presenting-sym

212 Migraine headache is uniquely exacerbated by light.

213 However, an association between eczema and headaches is not well established.

214 h increased risk of immediate postprocedural headache, largely owing to a nonlinear increase in risk

215 s included attack severity, attack duration, headache load (a composite score of attack frequency, se

216 Headache load improved by 99% (interquartile range 52%).

217 GSK2245035 induced CytoRS-AEs (most commonly headache, median duration <1 day) in 93% of participants

218 a subgroup of patients, acute stroke-related headache might be centrally driven.

219 symptoms, including fever >/=37.8 degrees C, headache, myalgia, cough, sore throat, runny nose and sp

220 al internuclear ophthalmoplegia (n = 1), and headache (n = 1).

221 mbosis (n = 3), cerebral infarction (n = 2), headache (n = 2), and myelofibrosis (n = 2) occurred in

222 he most frequent adverse events overall were headache (n = 22 [19%]), asthenia (n = 16 [14%]), and fa

223 6 [69.8%]), abdominal pain (n = 90 [54.2%]), headache (n = 87 [52.4%]), anemia (n = 83 [50%]), skin d

224 adverse events were fatigue (n=28 [19%]) and headache (n=20 [14%]).

225 cebo group (infusion site pain, n=1; tension headache, n=1); one patient in the placebo group had a s

226 monotherapy group included peripheral edema, headache, nasal congestion, and anemia.

227 ommon treatment-emergent adverse events were headache, nausea, and dissociation; the last-mentioned w

228 The most common reported adverse events were headache, nausea, and fatigue.

229 most common adverse events included fatigue, headache, nausea, and insomnia.

230 erse events in the two studies were fatigue, headache, nausea, and insomnia.

231 After the third dose, he presented with headache, nausea, and vomiting; a brain magnetic resonan

232 tients) related adverse events were fatigue, headache, nausea, diarrhea, dizziness, and vomiting.

233 The most common adverse events were fatigue, headache, nausea, rash, and insomnia.

234 ents occurring in more than one patient were headache (nilotinib group, n=2 [2%, including 1 after cr

235 fected adults with suspected meningitis (eg, headache, nuchal rigidity, altered mental status) were s

236 d atypical symptoms like chest tightness and headache occurred in 86% and 66%, respectively.

237 n the cirrhosis 24-week treatment group, and headache occurred in nine (29%) patients in the cirrhosi

238 d patients with chronic migraine (defined as headache of any duration or severity on >/=15 days per m

239 ion [triptans or ergots] was used to treat a headache of any severity or duration) per month during t

240 ch medication, if any, to use to prevent the headache of pediatric migraine has not been established.

241 therapeutic benefit of CGRP-mAb in reducing headaches of intracranial origin such as migraine with a

242 ere headache days, total cumulative hours of headache on headache days, or a >/=5-point improvement i

243 ofosbuvir, daclatasvir, and asunaprevir) and headache (one [17%] patient in each group).

244 order might cause only one clinical symptom (headache or seizure) and radiographically might show few

245 rt wheezing (OR = 1.92; 95% CI: 1.32, 2.79); headaches (OR = 1.81; 95% CI: 1.41, 2.58); watery, burni

246 severity for all symptoms ( P < .01) except headaches ( P = .054).

247 dominal pain, chest pain and/or dyspnea, and headache; P < .0001); median post-CT confidence was high

248 r of headache days (defined as days in which headache pain lasted >/=4 consecutive hours and had a pe

249 nts have suggested a role of the thalamus in headache pathophysiology.

250 puncture outcomes (immediate postprocedural headache, PDPH at 24-hour follow-up, and PDPH receiving

251 hway may be sufficient for the generation of headache perception.

252 iated with macitentan than with placebo were headache, peripheral edema, skin ulcer, anemia, upper re

253 rain, we conclude that the initiation of the headache phase of migraine depends on activation of meni

254 The headache phenotype was tension-type like in most cases.

255 patch, 12% [251 of 2022 participants]), and headache (placebo, 10% [199 of 2014 participants]).

256 gns and symptoms including rash, arthralgia, headache, pruritus, myalgia, and fever.

257 In the double-blind phase, headache, pyrexia, nasopharyngitis, sleep disorder, and

258 a longer attack duration, increased risk of headache recurrence, greater disability, and a longer pe

259 mized Investigation to Evaluate Incidence of Headache Reduction in Subjects With Migraine and PFO Usi

260 mized Investigation to Evaluate Incidence of Headache Reduction in Subjects With Migraine and PFO Usi

261 rences in reduction in headache frequency or headache-related disability in childhood and adolescent

262 Secondary outcomes were headache-related disability, headache days, number of tr

263 no significant between-group differences in headache-related disability, headache days, or the perce

264 rticipants in the placebo group, followed by headache, reported in 23 (57%), 25 (60%), and three (15%

265 fied subgroup analyses of postdural-puncture headache revealed no interactions between needle type an

266 The lesions can cause headache, seizures, focal neurological deficits, and hem

267 on with symptoms lasting longer than 1 week, headache, sensitivity to noise, fatigue, answering quest

268 -term complications reported so far include: headaches, severe photophobia, persistent foreign body s

269 found that green light exacerbates migraine headache significantly less than white, blue, amber or r

270 3%]), seizure (nine [2%] vs eight [2%]), and headache (six [2%] vs ten [3%]).

271 s [27%]), nasopharyngitis (seven [27%]), and headache (six [23%]).

272 Prominent clinical manifestations are headache, subacute encephalopathy, optic papillitis, inf

273 Subtraction analysis revealed that in headache sufferers infarctions were more often distribut

274 he as well as 50 patients with stroke but no headache symptoms.

275 ommon treatment-emergent adverse events were headache (ten [10%], ten [10%], and ten [10%] vs four [4

276 The most common adverse events overall were headache (tenofovir alafenamide 40 [14%] patients vs ten

277 of sufficient sleep had even higher odds of headache than eczema alone.

278 ic migraine resulted in a lower frequency of headache than placebo in this 12-week trial.

279 uscle tenderness prior to onset of occipital headache that eventually progresses into a full-blown mi

280 Migraine is characterized by severe headaches that can be preceded by an aura likely caused

281 etween the headache group as well as the non-headache there was no difference in infarct volumes, in

282 ionship, were pyrexia (four [3%] of 125) and headache (three [2%]).

283 event in the vaccine and placebo groups was headache (three [7%] people in the vaccine group vs four

284 Headache (twice-weekly treatment) and nasopharyngitis (o

285 Symptoms can include headaches, visual loss, pulsatile tinnitus, and back and

286 Criteria findings (>60 years, intoxication, headache, vomiting, amnesia, seizure, or trauma above th

287 igraine was 10% (5-20); chronic tension-type headache was 4% (2-9); chronic pelvic pain or prostatiti

288 Headache was reported in 10% of patients receiving NTCD-

289 The incidence of postdural-puncture headache was significantly reduced from 11.0% (95% CI 9.

290 Headache was the most common adverse event with BIIB074

291 ven with GSK2330672 vs one with placebo) and headache was the most frequent adverse event during trea

292 bdominal pain, chest pain and/or dyspnea, or headache were identified.

293 uch as increased pain, muscle stiffness, and headache were reported 50% to 67% of the time in large c

294 Nasopharyngitis and headache were the most common adverse events (idebenone,

295 d 36 [80%] of 45 in VRC 320) and malaise and headache were the most frequent systemic symptoms (22 [2

296 Vomiting, nausea, and headache were the only treatment-emergent adverse events

297 Headaches were associated with adherence only in the pla

298 Two (7%) adverse events (fatigue and headache) were deemed possibly related to treatment with

299 sociated with transient post-lumbar puncture headache, without increasing rates of persistent PDPH or

300 ing spontaneous reports of stomach upset and headache, yet dropout rates were comparable between grou